People · Operator
Named in public records as an officer, director or promoter · active 2008–2013 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juventas Therapeutics Inc | — | Biotechnology | Series B | $35.8M | $52.0M | 2008 |
| Celleration Inc | — | Other Health Care | Series A | $14.4M | $129.7M | 2011 |
| SironRX Therapeutics, Inc. | — | Other Health Care | Seed | $5.7M | $84.6M | 2011 |
| Orthodata Inc | — | Other Health Care | Pre-Seed | $320K | $9.9M | 2009 |
George Emont at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside George Emont on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| George Arida | 2 | 6 |
| Linda Tufts | 2 | 5 |
| Rahul Aras | 2 | 3 |
| Somu Subramaniam | 1 | 17 |
| Mark Wagner | 1 | 9 |
| Peter Shagory | 1 | 5 |
| Roger Newton | 1 | 4 |
| Marc Penn | 1 | 4 |
| Suzette Dutch | 1 | 3 |
| Christopher Geyen | 1 | 3 |
| Kevin Etzkorn | 1 | 3 |
| Troy Ignelzi | 1 | 3 |
| Julie Higginson | 1 | 1 |
| Sven Wehrwein | 1 | 1 |
| Merle Smith | 1 | 1 |
| Matthew Pollman | 1 | 1 |
| Timothy Prell | 1 | 1 |
| Pam Unger | 1 | 1 |
| James Boland | 1 | 1 |
| Matt Pollman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.